Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.54 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 2/20 | 0.52 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16600673 | 0.92 | LIPG (0.55) | CARM1PRMT6BCHELIPGSLC18A3 | |
| SCHEMBL21638171 | 0.92 | LIPG (0.55) | CARM1PRMT6BCHELIPGSLC18A3 | |
| SCHEMBL4468218 | 0.87 | CARM1 (0.56) | CARM1PRMT6BCHELIPG | |
| SCHEMBL21409412 | 0.85 | CARM1 (0.54) | CARM1PRMT6BCHEGRIN2DGRIN3B | |
| SCHEMBL16422780 | 0.85 | NAAA (0.54) | CARM1PRMT6BCHELIPGSLC18A3 | |
| SCHEMBL16600153 | 0.85 | DRD4 (0.55) | FAAHMGLLGRIN2DGRIN3BGRIN1 | |
| SCHEMBL27629882 | 0.85 | CARM1 (0.57) | CARM1PRMT6LIPGMGLLGRIN2D | |
| SCHEMBL23365208 | 0.83 | CARM1 (0.58) | CARM1PRMT6BCHEFAAHMGLL | |
| SCHEMBL18701756 | 0.83 | CARM1 (0.53) | CARM1PRMT6BCHELIPG | |
| SCHEMBL2297744 | 0.82 | CARM1 (0.59) | CARM1PRMT6MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| WO-2009082346-A1 | NEW ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS AND USES IN TREATMENTS OF OBESITY AND DIABETES MELLITUS - 087 | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ACACA, ACACB, ACAT1 | CARM1 2138/4885PRMT6 2084/4885BCHE 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.